3 Asian Stocks Estimated To Be Trading Up To 49.3% Below Intrinsic Value

Simply Wall St

Tue, February 17, 2026 at 7:43 AM GMT+9 4 min read

In this article:

0917.HK

+5.13%

2589.HK

+1.28%

2698.HK

-2.32%

9869.HK

-2.17%

6873.TW

-4.85%

Amidst global concerns about AI disruption and fluctuating economic indicators, Asian markets have shown resilience with Japan’s stock indices rising sharply and Chinese stocks edging higher as the Lunar New Year approaches. In this environment, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Click here to see the full list of 226 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

We’re going to check out a few of the best picks from our screener tool.

VITZROCELLLtd

Overview: VITZROCELL Co., Ltd. is involved in the production and sale of lithium batteries in South Korea, with a market cap of ₩912.86 billion.

Operations: The company’s revenue segment is primarily from its Battery Business, amounting to ₩236.05 billion.

Estimated Discount To Fair Value: 49.3%

VITZROCELL Ltd. is trading at ₩20,500, significantly below its estimated future cash flow value of ₩40,396.76, indicating it may be undervalued based on cash flows. Despite a recent stock split and strong past earnings growth of 62.4%, its forecasted annual earnings growth of 20.9% lags behind the Korean market’s 29.7%. However, revenue is projected to grow faster than the market at 17.1% annually over the next few years.

The analysis detailed in our VITZROCELLLtd growth report hints at robust future financial performance.

Unlock comprehensive insights into our analysis of VITZROCELLLtd stock in this financial health report.

KOSDAQ:A082920 Discounted Cash Flow as at Feb 2026

Qunabox Group

Overview: Qunabox Group Limited offers marketing services, merchandise sales, and other services in Mainland China with a market cap of approximately HK$6.52 billion.

Operations: The company’s revenue is primarily derived from merchandise sales, totaling CN¥189.38 million.

Estimated Discount To Fair Value: 23.7%

Qunabox Group is trading at HK$24.6, below its estimated future cash flow value of HK$32.24, suggesting undervaluation based on cash flows. The company anticipates a significant turnaround with projected profits between RMB 270 million and RMB 330 million for 2025, reversing a prior loss due to strategic R&D investments in AI applications. Recent share buybacks aim to enhance shareholder returns. Additionally, the strategic alliance with Dubai’s ruling family supports international AI expansion efforts.

Story Continues  

Upon reviewing our latest growth report, Qunabox Group's projected financial performance appears quite optimistic.

Click to explore a detailed breakdown of our findings in Qunabox Group's balance sheet health report.

SEHK:917 Discounted Cash Flow as at Feb 2026

Takara Bio

Overview: Takara Bio Inc. operates in the fields of reagents, equipment, contract services, and genetic medicine across Japan, China, other parts of Asia, the United States, Europe, and internationally with a market cap of ¥114.52 billion.

Operations: Takara Bio Inc.'s revenue is derived from its operations in reagents, equipment, contract services, and genetic medicine across various global markets including Japan, China, other parts of Asia, the United States, and Europe.

Estimated Discount To Fair Value: 42.6%

Takara Bio, trading at ¥951, is significantly below its estimated future cash flow value of ¥1657.28, indicating potential undervaluation. Despite recent volatility and an expected net loss for the fiscal year ending March 2026, revenue growth forecasts surpass the Japanese market average. However, the dividend yield of 1.79% is not well covered by earnings or free cash flows. Takara Holdings’ proposed acquisition could lead to delisting from TSE if successful.

Our expertly prepared growth report on Takara Bio implies its future financial outlook may be stronger than recent results.

Get an in-depth perspective on Takara Bio's balance sheet by reading our health report here.

TSE:4974 Discounted Cash Flow as at Feb 2026

Turning Ideas Into Actions

Investigate our full lineup of 226 Undervalued Asian Stocks Based On Cash Flows right here.

Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.

Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Looking For Alternative Opportunities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include KOSDAQ:A082920 SEHK:917 and TSE:4974.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info